Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials
暂无分享,去创建一个
J. Byrd | U. Jaeger | T. Kipps | T. Shanafelt | A. Howes | S. O'brien | J. Moslehi | Jennifer R. Brown | J. Burger | A. Tedeschi | G. Fraser | M. Dreyling | J. Vermeulen | S. Coutre | S. Rule | L. Styles | P. Ghia | M. Dilhuydy | F. Cymbalista | P. Cramer | P. Hillmen | F. Clow | M. Wildgust | D. James | M. Mahler | M. Todd | Rudolph Valentino
[1] Anne Quinquenel,et al. The Impact of Atrial Fibrillation on Subsequent Survival of Patients Receiving Ibrutinib As Treatment of Chronic Lymphocytic Leukemia (CLL): An International Study , 2016 .
[2] J. Carey,et al. Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation. , 2016, Oncology.
[3] B. Cheson,et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. , 2016, Blood.
[4] E. W. Van Den Neste,et al. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study , 2016, British journal of haematology.
[5] Jeffrey A Jones,et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. , 2016, The Lancet. Oncology.
[6] J. Healey,et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. , 2016, Blood.
[7] Nibedita Bandyopadhyay,et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.
[8] M. Hallek,et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. , 2016, The Lancet. Oncology.
[9] T. Kipps,et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. , 2015, The New England journal of medicine.
[10] P. Noseworthy,et al. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) , 2017, Leukemia & lymphoma.
[11] A. Wiestner,et al. Atrial Fibrillation in CLL/SLL Patients on Ibrutinib , 2015 .
[12] K. Rai,et al. Characterization of Atrial Fibrillation and Bleeding Risk Factors in Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Retrospective Cohort Study of Administrative Medical Claims Data in the United States (US) , 2015 .
[13] D. Roden,et al. Abstract 14587: Proarrhythmic Effects of Ibrutinib, a Clinically Approved Inhibitor of Bruton’S Tyrosine Kinase (BTK) Used in Cancer Therapy , 2015, Circulation.
[14] Michael L. Wang,et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.
[15] Jeffrey A Jones,et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.
[16] C. Tam,et al. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. , 2014, Blood.
[17] M. Keating,et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. , 2014, Blood.
[18] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[19] M. Ezekowitz,et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.
[20] M. Keating,et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation , 2014, Leukemia.
[21] J. Byrd,et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.
[22] J. Healey,et al. Atrial fibrillation is associated with increased mortality: causation or association? , 2013, European heart journal.
[23] Tommy Andersson,et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case–control study , 2013, European heart journal.
[24] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[25] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[26] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[27] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[29] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[30] Michael L. Wang,et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.